Answers are grounded in this paper and cite their sources.
Demonstrates that hookworm-derived metabolites suppress inflammation in colitis, suggesting new therapeutic avenues.
Iatrogenic hookworm therapy shows promise for treating disorders that result from a dysregulated immune system, including inflammatory bowel disease (IBD). Using a murine model of trinitrobenzenesulfonic acid-induced colitis and human peripheral blood mononuclear cells, we demonstrated that low-molecular-weight metabolites derived from both somatic extracts (LMWM-SE) and excretory-secretory products (LMWM-ESP) of the hookworm, Ancylostoma caninum , display anti-inflammatory properties.
No takes yet. Share an insight, caveat, or question.
Wangchuk et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: